The Profit Case Strengthens, but the Valuation Recovery Has Arrived

Results vs. Consensus

Q1 FY2027: quarter ended June 30, 2026

Year-over-year comparisons

Quarter-over-quarter comparisons

Revenue: The prior quarter’s sales miss did not signal a collapse in prescription demand. Revenue grew 7.7%, with oncology providing $3.564B of the $7.553B increase. Lower branded prices still suppress distribution sales, but higher prescription volumes and specialty activity support the service economics. Revenue returning above expectations strengthens our earlier distinction between drug-price exposure and earnings exposure.

Margins: Adjusted gross profit grew 12.7% against 9.8% expense growth. Expenses absorbed 56.84% of adjusted gross profit, down from 58.33% a year earlier, a 149 basis point improvement. The operating-leverage pillar is stronger than at Q4, when incremental expense efficiency had nearly stalled. Sequential margin declines reflect a demanding seasonal comparison, including the annual RxTS reverification peak, and do not overturn the year-over-year improvement.

EPS: Adjusted earnings grew 14.1%; repurchases lifted per-share growth to 20.2%, while the tax rate was essentially unchanged year over year. GAAP EPS fell because common shareholders absorbed $374M of redemption-value adjustments. Those charges are noncash today but represent ownership economics that adjusted growth excludes. The $4.78 gap between GAAP and adjusted EPS therefore deserves more attention than the modest consensus surprise.

Segment Performance

North American Pharmaceutical: the fee model passes another test

Adjusted profit of $894M increased $145M, with margin expanding to 1.03% from 0.91%. Specialty distribution to health systems and strategic accounts, together with product launches, mattered more to profit than the slower branded-sales denominator. Two successive quarters of year-over-year margin expansion now follow the Q3 contraction flagged in our last recap.

Assessment: We raise FY2027 segment profit growth to 9.5% from 7.5%, following management’s move to the high end of guidance. This supports the core scale thesis without assuming that a quarter helped by launch timing repeats indefinitely.

Oncology & Multispecialty: organic growth survives the anniversary

Profit rose to $405M and margin expanded 16 basis points. Management identified 15% organic profit growth excluding Core Ventures, compared with 13% in Q4; reported growth of 41% still includes the acquisition comparison. Revenue excluding Core grew about 24%, which also includes new provider relationships and business wins.

Assessment: The prior 13% organic-growth test is met, supporting our unchanged 15.5% full-year profit estimate. The distinction between same-practice growth and additions remains useful: expanding the network can sustain growth, but the 24% sales figure is not evidence of that rate within existing practices.

Prescription Technology Solutions: access economics remain intact

RxTS earned $303M at a 19.35% margin, up 59 basis points year over year. Access demand supported profit growth of 13%, while logistics and access volumes lifted revenue 9%. The decline from Q4’s $322M profit follows the annual reverification season.

Assessment: This delivers at the midpoint of the 11%–15% annual profit range after last year’s investment increase. We retain 13% FY2027 profit growth; access-services demand continues to be a more useful indicator of the network business than logistics-heavy revenue alone.

Medical-Surgical: sales recovery has not reached earnings

Revenue grew 4%, but profit declined $49M to $195M and margin contracted 211 basis points. Product mix and a one-time administrative expense outweighed extended-care growth. The expense was not separately quantified, so its eventual reversal cannot explain away the entire decline.

Assessment: Our unchanged 2% full-year profit estimate now requires approximately 8.9% growth over the remaining nine months. Stabilization has become a harder delivery test than in May, even as financing milestones are completed. A weaker medical recovery would reduce consolidated earnings and the value available on separation.

Corporate and Other: Corporate expense rose only $6M to $144M, leaving our $610M annual assumption intact. Norway contributed no profit after its January sale, compared with $13M a year ago; that comparison remains a $25M headwind in Q2.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Management remained assured, with more direct evidence of core-profit resilience than in Q4. The new finance leadership acknowledged launch timing and held the cash outlook steady, which gives the confidence a useful limit rather than implying every first-quarter benefit is repeatable.

1. Launch timing funds a raise and more investment

The company now expects core pharmaceutical profit growth at the top of its prior range and will accelerate growth and technology investment in the second half. That combination makes the outlook more credible than simply carrying Q1’s margin improvement forward: part of today’s benefit funds future capacity.

Assessment: Our 9.5% annual forecast implies 6.8% core-profit growth in the remaining quarters. That is consistent with the segment’s 5%–8% long-term range, so slower growth from here can still fulfill the strengthened thesis. Investment returns are prospective; we add no separate AI valuation premium.

2. Oncology capacity matters more as large acquisitions lap

The operating plan emphasizes physician recruitment, geographic expansion and greater throughput at existing practices. The US Oncology Network now has about 3,400 providers, while distribution and group-purchasing relationships reach more than 14,000. Those are different networks, with additional service opportunities inside the larger base.

Assessment: Provider expansion can generate both distribution earnings and practice, data and trial-service revenue. The economic case rests on serving more patients and retaining more of the service relationship, not on repeating a transaction the size of Florida Cancer Specialists. We keep growth near the middle of the long-term oncology range.

3. GLP-1 access creates an opportunity beyond physical distribution

The Medicare GLP-1 bridge program began receiving McKesson support in July, after this reporting quarter. Management described eligibility, prior-authorization connectivity and claims services, with 95% of submitted authorization requests receiving a determination within 30 minutes.

Assessment: Faster authorization can make the network more useful to payers and manufacturers, but the metric measures decision speed, not approvals or revenue. It supports the forward access-services case while leaving our RxTS estimate unchanged; June-quarter growth already stands on existing programs.

4. Wellverse is progressing toward independence, with a weaker profit base

Apollo’s $1.25B minority investment closed June 1 and the $2.25B secured Term Loan B followed June 9. Those fulfill the financing milestones we carried from Q4. Medical-Surgical is expected to begin using the Wellverse name in January 2027, a brand transition rather than a completed separation.

Assessment: Funding and a distinct identity fulfill the financing milestones, but portfolio reshaping remains AT RISK. Neither resolves the IPO versus full-exit endpoint first raised in Q3, recurring stranded costs or the weaker medical profit trend. The earlier second-half calendar 2027 full-separation objective remains an outstanding commitment, rather than a newly reaffirmed date. Our valuation includes the medical earnings and associated financing costs together, with no additional transaction premium.

5. Redeemable interests remain an economic claim

The quarter includes $293M of redemption-value adjustment for the Apollo interest and $81M for Core Ventures. Together, $374M is approximately $3.14 per diluted share. The redeemable balance rose to $2.563B, principally from $1.238B of net Apollo equity proceeds and those adjustments, rather than from remeasurement alone.

Assessment: The risk raised in May is now larger in dollars, but remains a question of value retained by common shareholders and future settlement, not an immediate $374M cash outflow. We continue to deduct ordinary adjusted minority earnings in the forecast and retain an EMERGING earnings-quality risk.

6. Better working capital has not lifted the cash guide

Operating cash outflow improved to $220M from $918M. The cash contribution from payables increased by $1.826B, more than the $698M operating cash-flow improvement, while receivables, inventories and taxes offset part of the benefit. Capital expenditure fell to $152M from $189M, bringing the free-cash-flow improvement to $735M.

Assessment: The improved quarter is welcome, but does not by itself establish a structural cash run rate. We retain $4.7B annual free cash flow, roughly 90% of projected adjusted earnings. The $5B buyback plan plus dividends still exceeds internally generated cash, making separation financing an important part of this year’s capital return.

7. Pricing resilience and policy exposure are different tests

Management says more than 95% of branded drugs are covered by fee-for-service arrangements, helping explain why lower drug prices have had little profit effect. The 340B proposal and future physician reimbursement changes expose a broader set of hospital, pharmacy and practice economics than the distribution contract alone.

Assessment: This quarter reinforces the CONTAINED GLP-1 margin risk. It does not remove the EMERGING policy risk: the net effect depends on final rules, reimbursement and customer behavior. We keep the 19x valuation multiple rather than awarding a premium for an unresolved policy outcome.

8. The CFO transition preserves the operating framework

The new CFO’s first call retains the existing capital-allocation priorities and segment targets while narrowing the tax and share assumptions. Financing is now visible in interest and minority expense, allowing a more complete earnings bridge than the headline buyback figure provides.

Assessment: Continuity of financial disclosure supports the transition commitment from Q4. The next test is delivery: the tax rate rises, interest accumulates across a full year of debt and acquisitions become comparable. Those are concrete offsets to operating progress, even with disciplined execution.

Guidance & Outlook

The revised EPS range implies 13%–15% growth against FY2026 reported adjusted EPS, or 15%–17% against the $38.37 base excluding Norway and the prior US Oncology Network gain. The stronger consolidated profit outlook gives the raise operating substance, unlike the accounting-only increase at our FY2026 Q1 initiation.

Our $44.60 full-year estimate leaves $34.67 after Q1, 12.4% above the comparable remaining-nine-month EPS last year. The path is uneven: Q2 laps a $51M oncology gain and $25M of Norway profit, while Q4 remains seasonally strongest in core distribution and reverifications. A strong Q1 does not eliminate those comparisons or the later investment burden.

Analyst Q&A Highlights

How much of the core-profit acceleration repeats?

Question: The closing exchange challenged why 19% first-quarter pharmaceutical profit growth leaves only about 6.8% implied for the rest of the year, asking about launch timing, utilization and comparisons.

Response: Brian Tyler acknowledged earlier-than-expected generic benefits. Kenny Cheung separately identified both branded and generic launches, plus accelerated second-half investment; expected returns begin later.

“That obviously will come at the expense of later quarters, we benefited early.”
— Brian S. Tyler, CEO & Chairman

Assessment: The answer resolves a material part of the apparent conservatism: the annual guide contains timing reversal as well as investment. We accept the 9.5% full-year core forecast, without moving it toward the first-quarter growth rate.

Is oncology growth organic or still acquisition-driven?

Question: One exchange sought the acquired contribution and Florida Cancer Specialists’ performance; a later exchange asked how organic growth compares with the market and how providers can expand it.

Response: Cheung separated 24% revenue and 15% profit growth excluding Core Ventures. Tyler described acquisition execution at the favorable end of initial expectations, then emphasized recruiting, geography and patient capacity; Cheung confirmed the 15% profit growth was organic.

Assessment: The response supplies the missing anniversary evidence behind our prior forecast. It supports a mid-teens profit assumption, while the lack of separate same-practice and provider-addition rates prevents assigning all outperformance to market-share gains.

Can GLP-1 demand survive changes in coverage and cash access?

Question: The discussion tested employer coverage and direct-to-consumer activity against the distribution growth outlook. Response: Tyler described healthy demand in both insured and cash channels, with no major overall coverage shift observed.

Assessment: Broad participation reduces reliance on one route to the patient. It does not show equal profitability across channels, so our forecast relies on service demand and observed margins rather than treating all GLP-1 revenue as equally valuable.

Does distribution protection extend to 340B and physician reimbursement?

Question: The exchange addressed 340B proposals and other policy exposure. Response: Tyler said the proposal was still under review and discussed uncertain future Part B terms; Cheung explained why fee-based distribution compensation is less sensitive than reported sales to drug prices.

Assessment: Management answered the mechanism but declined to size a policy outcome before final terms. That is a reasonable limit. The existing policy discount remains warranted because the practices and customers using McKesson’s services may be affected differently from its distribution fees.

Why is cash flow not keeping pace with earnings?

Question: The challenge was the multi-year gap between rising earnings and the unchanged cash-flow outlook, not merely the usual negative first quarter. Response: Cheung cited better working-capital execution, technology and inventory management, while retaining the range early in the year.

Assessment: The stronger first quarter supports his direction of travel; it does not answer how much improvement will survive payment timing. We retain $4.7B rather than building a prospective cash raise into buybacks or valuation. Cash conversion remains an open commitment from Q4.

What They’re NOT Saying

1. The dollar size of the launch benefit and later investment. Without both, the annual bridge can be tested against the guide but not decomposed into recurring growth and timing with precision.
2. A complete Medical-Surgical profit recovery and stranded-cost bridge. Neither the administrative item nor recurring separation costs is sized sufficiently to establish net common-shareholder value.
3. The settlement timing of redeemable minority claims. The filing identifies the balances and adjustments, but the earnings discussion does not turn them into a usable cash-payment schedule.
4. A numerical bridge from working-capital projects to the cash guide. The unchanged range appropriately leaves some first-quarter improvement uncapitalized.
5. Profit by GLP-1 channel and detailed same-practice oncology growth. Both would clarify how much growth comes from stronger unit economics versus expanding the activity base.

Market Reaction

• Pre-print: MCK closed August 5 at $877.23, up 6.9% year to date, 11.9% over 30 days and 23.6% over twelve months. Its preceding 52-week closing range was $659.01–$995.69; the S&P 500 had gained 12.8% year to date.
• Initial response: After-hours reports showed a gain of roughly 1.7% following the beat and guidance increase.
• August 6 session: The stock opened at $912.19, up 4.0%, traded between $840.00 and $912.50, and closed at $871.38, down $5.85 or 0.7%.
• Participation: Volume was 1.6M shares against a 1.1M 30-day average, 1.5 times normal. The S&P 500 fell 0.2%, leaving MCK approximately half a percentage point behind.

The reversal shows that the beat did not produce a durable session gain after an 11.9% pre-print monthly rally. Launch timing, an unchanged cash outlook and weaker Medical-Surgical profit are plausible reasons to resist extrapolating the opening enthusiasm. That is our interpretation of the disclosed tensions, not a measured attribution of the selloff.

More consequential for the rating is the starting valuation. The reaction close is well above the $736.09 price behind May’s upgrade. Our FY2027 estimate rises only $0.40, and the stock now trades at 19.5x that estimate, already above the 19x multiple used in our prior target. Future return depends increasingly on another year of earnings delivery.

Street Perspective

Debate: Durable core earnings or borrowed growth?

Bull view: Specialty volumes and fee-based compensation let profit grow despite lower drug prices.

Bear view: Early launches and later spending mean the first-quarter pace overstates the annual trajectory.

Our take: Both observations can hold. The high end of annual guidance is credible, but repeating 19% growth is not our base case.

Debate: Specialty platform or acquisition arithmetic?

Bull view: Fifteen percent organic oncology profit growth and steady RxTS margins support service-led compounding.

Bear view: Provider expansion, reimbursement uncertainty and minority ownership make consolidated growth different from returns to common shareholders.

Our take: Organic delivery strengthens the operating case. We still include minority costs and favor a measured valuation over a higher multiple for the acquisition headline.

Debate: Capital release or a more complicated claim on cash?

Bull view: Completed financing advances separation and enables repurchases alongside operating investment.

Bear view: Medical profit is falling, recurring costs remain open and guided buybacks exceed free cash flow.

Our take: The transactions improve flexibility, but do not create a second pool of unencumbered value. At the recovered share price, the stock needs future earnings growth to earn its return.

Our Estimates & Valuation Framework

The updated FY2027 bridge gives $44.58 before rounding to our $44.60 estimate. Raising core-profit growth to 9.5% adds approximately $0.48 per share; moving the tax rate from 18% to 18.5% costs $0.29, and lowering shares from 117M to 116.5M adds $0.19. Other segment growth and financing assumptions are unchanged. The resulting 10.6% operating-profit growth lies inside the new 9%–13% range.

FY2028 operating assumptions: Our new estimate uses 6.5% core pharmaceutical profit growth, 14.5% oncology, 11.5% RxTS and 2% Medical-Surgical. The retained growth businesses sit inside their long-term ranges, with investment helping capacity rather than creating a separate step-change in profit. Corporate expense rises to $630M, interest stays at $400M, tax remains 18.5%, adjusted minority expense increases to $340M and shares average 113M. These are our assumptions, not company guidance.

The share estimate assumes the FY2027 repurchases reduce the starting share base and roughly $3B of FY2028 repurchases extend that reduction, below this year’s financing-supported $5B pace. We assume no new large acquisition and no extra separation proceeds. The forecast retains Medical-Surgical on a consolidated basis as a valuation proxy; an actual IPO or distribution would require allocating earnings, debt and the value of any distributed shares consistently.

Twelve-month return cases from the August 6 close of $871.38

Target bridge: We keep the 19x multiple used in May. On the same FY2027 earnings period, the revision raises value only $7.60, from $839.80 to $847.40. Rolling to our $50.27 FY2028 estimate adds $107.73, producing $955.13. Thus most of the higher target comes from valuing another year of earnings, not from this quarter’s $0.40 revision or a richer multiple.

The twelve-month horizon now ends in August 2027, when FY2027 will be complete and FY2028 will be underway. That supports using FY2028 earnings, while making the additional forecast risk explicit. It also gives the positive operating evidence room to matter: retaining FY2027 earnings at 19x would imply a 2.3% negative total return. We do not use the roll to justify a larger premium; the multiple still discounts cash conversion, policy and separation uncertainty.

Downside: The bear case assumes FY2028 core profit falls 5% as fee or mix pressure reaches earnings, oncology and RxTS grow 8%, and Medical-Surgical falls 5%. Corporate expense of $670M, interest of $440M, 19% tax, $360M minority expense and 116M shares give $43.30 EPS. A 16x multiple implies approximately 20% downside including dividends. The bull case uses 8%, 16%, 13% and 4% segment growth, respectively, with $610M corporate expense, $380M interest, 18% tax, $325M minorities and 111M shares, giving $52.83 EPS at 21x.

Rating support: Our base total return is 10.0%, including four dividends at the new $0.94 quarterly rate, against an unchanged 8% S&P 500 assumption. Roughly two points of prospective excess return is insufficient for Outperform given the 20% bear-case loss and the added FY2028 assumptions. At an unchanged 17.3x FY2028 multiple, the modeled earnings alone do not deliver the target; reaching 19x remains necessary. A $100M recurring pretax cost would reduce FY2028 EPS by about $0.72 and value by roughly $14 at 19x.

Thesis Scorecard Post-Earnings

Prior commitments: Apollo closing and the additional term loan are delivered, oncology clears the organic-growth floor and RxTS is tracking its annual profit range. Core pricing insulation has another quarter of support. Medical profit stabilization has not arrived; the annual cash, tax, interest, share and minority-expense tests remain open. Neither the brand transition nor the financing closes the remaining separation commitments.

What changes our view: Evidence that launch-adjusted pharmaceutical profit sustains the high end of guidance, organic oncology remains inside 13%–16%, and working-capital improvements lift recurring cash would increase confidence in the FY2028 earnings bridge. Flat or declining core profit, oncology below its 13% floor, a failed medical recovery or recurring costs that materially erode that bridge would move us toward the downside case. A lower price or a supported earnings increase that restores meaningful excess return would reopen Outperform.

Overall: The operating thesis has strengthened without eliminating the existing financial and policy risks. The downgrade reflects a smaller valuation opportunity after the price recovery, not a reversal of the specialty or fee-based distribution case.

Action: Downgrade to Hold from Outperform, conviction 6. We expect returns broadly in line with the market over twelve months. The business is delivering, but the stock now requires another year of execution and some multiple recovery to offer a modest prospective advantage over the S&P 500.